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ABSTRACT  24 
Importance 25 
Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in 26 
multiple myeloma (MM). Most studies were small and varied in terms of patient population, 27 
treatment, and MRD assessment methods.  28 
Objective 29 
To evaluate the utility of MRD detection in patients with newly diagnosed MM. 30 
Data Sources 31 
A Medline search was conducted for articles published in English between January 1990 and 32 
January 2016.  33 
Study Selection 34 
Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS) 35 
in A? 20 patients following treatment. Among 405 articles identified, 21 met the initial eligibility 36 
criteria and were included in the analysis.  37 
Data Extraction and Synthesis 38 
Information on patient characteristics, treatment, MRD assessment, and outcomes were 39 
extracted using a standard form. 40 
Main Outcome Measures 41 
The impact of MRD status on PFS and OS was assessed by pooling data from relevant trials. 42 
Data were adjusted to allow for different proportions of patients with MRD in different studies, 43 
and analyzed using the Peto method. Forest plots were created based on Cox model analysis. 44 
Other pre-specified research questions were addressed qualitatively.  45 
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Results 46 
Fourteen studies (n = 1,273) provided data on the impact of MRD on PFS, and 12 studies (n = 47 
1,100) on OS. Results were reported specifically in patients who had achieved conventional 48 
complete response (CR) in 5 studies for PFS (n = 574) and 6 studies for OS (n = 616). MRD-49 
negative status was associated with significantly better PFS overall (Hazard ratio [HR] 0.41; 95% 50 
confidence interval [CI] 0.36 ?0.48; P < .0001) and in studies specifically looking at CR patients 51 
(HR 0.44; 95% CI 0.34 ?0.56; P < .0001). OS was also favorable in MRD-negative patients overall 52 
(HR 0.57; 95% CI 0.46 ?0.71; P < .0001) and in CR patients (HR 0.47; 95% CI 0.33 ?0.67; P < 53 
.0001). Tests of heterogeneity found no significant differences among the studies for PFS and 54 
OS.  55 
Conclusions and Relevance 56 
MRD-negative status after treatment for newly diagnosed MM is associated with long-term 57 
survival. These findings provide quantitative evidence to support the integration of MRD 58 
assessment as an endpoint in clinical trials of MM.  59 
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INTRODUCTION  60 
A substantial proportion of patients with multiple myeloma (MM) can now expect to achieve 61 
clinical complete response (CR), as a result of recent therapeutic advances.1,2 These advances 62 
include the combined use of immunomodulatory drugs (thalidomide, lenalidomide, or 63 
pomalidomide) and proteasome inhibitors (bortezomib or carfilzomib), along with high-dose 64 
therapy with autologous stem cell transplantation (ASCT) in eligible individuals. CR rates are 65 
likely to continue to increase with incorporation of novel combinations of therapies.3 66 
Nevertheless, most patients who achieve CR eventually relapse,1 suggesting that a small but 67 
clinically relevant population of myeloma cells not detected by current techniques, persists. 68 
Assays with greater sensitivity have been developed to detect minimal residual disease (MRD), 69 
including multiparameter flow cytometry (MFC), allele-specific oligonucleotide quantitative 70 
polymerase chain reaction (ASO-qPCR), and next-generation sequencing (NGS) techniques.3,4 71 
Potential applications of MRD assessment in MM management are numerous.1,3,5,6 It is already 72 
considered an important prognostic factor.7 MRD testing could be used to monitor response to 73 
therapy; the presence or absence of MRD may also inform subsequent treatment decisions, 74 
including consolidation and maintenance.7 Historically, due to the complexity of conventional 75 
MRD assays, evaluations were limited to a small number of patients. Recent development of 76 
MFC and NGS-based methods has allowed for MRD assessment in larger studies. To understand 77 
the real impact of MRD on outcomes from small-to-medium-sized studies, we performed a 78 
meta-analysis of all published data regarding the utility of MRD detection in patients with newly 79 
diagnosed MM (NDMM).  80 
 81 
METHODS 82 
Literature search and article selection 83 
A Medline search was performed for articles published in English between January 1990 and 84 
January 2016, using the MĞ^, ƚĞƌŵƐ  “ŵƵůƚŝƉůĞ ŵǇĞůŽŵĂ ? E  “ŶĞŽƉůĂƐŵ ? ƌĞƐŝĚƵĂů ? and the 85 
non-DĞ^,ƚĞƌŵƐ “DZ ? ? “ŵǇĞůŽŵĂ ?, ŶĚ “ŵŝŶŝŵĂůƌĞƐŝĚƵĂůĚŝƐĞĂƐĞ ?. Eligible articles included 86 
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those that reported on controlled trials, randomized controlled trials, or patient cohort studies 87 
with MRD status and survival outcomes progression-free survival (PFS) or overall survival (OS) in 88 
20 or more NDMM patients following therapy. Patients could have received any type of 89 
treatment except allogeneic stem cell transplantation (alloSCT), and MRD could be assessed by 90 
any method (MFC, ASO-qPCR, or NGS), but analysis was restricted to techniques with a limit of 91 
detection of 0.01% or lower. Trials were excluded if they: included only patients with 92 
relapsed/refractory MM (RRMM) or smoldering myeloma; assessed MRD in apheresis product; 93 
or reported on the same study population used in an already-included trial.  94 
Data extraction 95 
If primary data were not accessible, survival graphs from relevant trials were carefully 96 
measured and a computer program was written to reconstruct the individual survival and 97 
censoring times from these measurements. Articles were scrutinized to ensure that all P values, 98 
confidence intervals (CIs), hazard ratios (HRs), numbers of events/deaths, and median survival 99 
times and durations of patient follow-up matched those reported. There was a PFS curve but 100 
not an OS curve for one study.8 However, P values and percentages at particular times were 101 
provided for the OS data, which enabled censored values to be used from the PFS curves; it was 102 
therefore possible to use the additional information from the paper to derive the survival 103 
times. For the pooled analysis, data were adjusted to allow for the different proportions of 104 
patients with MRD in the different studies. P values are for adjusted log-ƌĂŶŬʖ2 tests.  105 
 106 
Statistical analysis 107 
For a pooled analysis of all studies reporting survival data, PFS and OS curves were generated.9 108 
This method adjusts for the different proportions of MRD positivity and negativity in each 109 
study, thereby avoiding inappropriate bias potentially generated by studies with high or low 110 
proportions of MRD positivity. The method produces an adjusted log-rank ʖ2 statistic to 111 
evaluate the significance of any differences between MRD positivity and negativity. It also 112 
provides a non-proportional hazards-based equivalent to performing a Cox model analysis 113 
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stratified by study or group. If the hazards are proportional, the results will be similar to such a 114 
Cox model analysis, which was the case in all such analyses in this report.  115 
The overview methodology described in detail by Peto10 was applied. In brief, for PFS and OS, 116 
the expected number (E) of events was derived in the MRD-positive and MRD-negative groups 117 
for each study, assuming no difference between the MRD groups. This was compared with the 118 
observed number (O) of events and the differences (O-Es) were then tested for heterogeneity 119 
to see whether the scatter of results was unexpected. The sum of [O-E]2/variance should be 120 
ĚŝƐƚƌŝďƵƚĞĚĂƐʖ2n-1 if the scatter is random, where n is the number of studies.  121 
HR forest plots were then generated using the inverse variance weighting method, as described 122 
in detail by Whitehead and Whitehead.11 Cox proportional hazards model analysis was 123 
performed for each study, generating HR and CIs, and the required variance. An overall Cox 124 
model analysis was run on the whole dataset, stratified by study to generate similar statistics 125 
for the total of all the studies combined. The size of the solid squares (Figures 2A, 2B, 3A, and 126 
3B) is proportional to the amount of information each trial contains (the inverse of the 127 
variance). 95% CIs are shown for the individual trials. For the overall result, 95% CIs are also 128 
given (open diamonds in the forest plot). The proportional hazards assumption was checked for 129 
the Cox model analyses using log ?log plots and Schoenfeld residuals and any departures from 130 
proportionality were extremely minor. 131 
There were no PFS events in the MRD-negative group in one study12 and no OS events in the 132 
MRD-negative group in another study,8 making it impossible to derive CIs and variance for Cox 133 
model HRs. In these two cases, an odds ratio approach was used to derive CIs and variance, 134 
incorporating the correlations between odds ratios and HRs which were all strong (r > .988). 135 
Statistical analyses were performed with Stata v13.0, or purpose-written Digital Visual Fortran 136 
Version 6.0A software. Hypothesis tests were 2-sided. 137 
 138 
RESULTS 139 
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Literature search 140 
The initial search yielded 405 articles, and 25 additional articles were identified from the 141 
reference sections of recently published articles on the topic. After applying eligibility criteria 142 
21 studies were included in the qualitative assessments (Figure 1).8,12 ?30  Of the 21 articles 143 
identified, 13 involved patients with NDMM and in nine articles it was not reported whether 144 
the population was limited to NDMM patients. Sixteen articles involved ASCT-eligible patients 145 
and one involved ASCT-ineligible patients; the remaining four studies included both ASCT-146 
eligible and ASCT-ineligible patients. The primary MRD assay that was evaluated was MFC (n = 147 
9); PCR (n = 11), or NGS (n = 1). 148 
Fourteen studies (n = 1,273) reported information on the impact of MRD on PFS and twelve 149 
assessed the impact of MRD on OS (n = 1,100); these studies were therefore included in the 150 
overall quantitative meta-analysis (Supplementary Table). Twelve publications reported 151 
conventional CR7 at the time of MRD measurement.6,8,19,21 ?27,31 However, further investigation 152 
identified potential duplication of data across some studies and led to the exclusion of five 153 
additional articles from the quantitative analysis in CR patients.21 ?24,27 154 
The impact of MRD status on survival outcomes 155 
The overall prognostic value of MRD status in terms of PFS was assessed in 14 studies involving 156 
1,273 patients (660 MRD-negative, 613 MRD-positive).8,12 ?14,16 ?18,24,25,28 ?31 The impact of MRD 157 
status on OS was assessed in 12 studies involving 1,100 patients (599 MRD-negative, 501 MRD-158 
positive).6,8,13,14,16 ?19,24,25,28,31 Compared with MRD positivity, MRD negativity was associated 159 
with better PFS (HR 0.41; 95% CI 0.36 ?0.48; P < .0001) (Figure 2A) and OS (HR 0.57; 95% CI 160 
0.46 ?0.71; P < .0001) (Figure 2B). Median PFS was 54 months for MRD-negative patients and 26 161 
months for MRD-positive patients (Figure 2C); median OS was 98 and 82 months, respectively 162 
(Figure 2D). dĞƐƚƐŽĨŚĞƚĞƌŽŐĞŶĞŝƚǇĨŽƵŶĚŶŽƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞƐĂŵŽŶŐƚŚĞƐƚƵĚŝĞƐĨŽƌK^ ?ʖ2 163 
= 8.81, 11 df; P A? ? ? ? ? ?ďƵƚƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞƐĂŵŽŶŐƚŚĞƐƚƵĚŝĞƐĨŽƌW&^ ?ʖ2 = 42.1, 13df; P < 164 
0.001).  This was a result of 2 very small studies,12,16 which showed unusually large differences; 165 
the Roussel et al. study also had no events occurring in MRD negative patients. When these 2 166 
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ƐƚƵĚŝĞƐǁĞƌĞĞǆĐůƵĚĞĚƚŚĞƚĞƐƚĨŽƌŚĞƚĞƌŽŐĞŶĞŝƚǇǁĂƐŶŽůŽŶŐĞƌƐŝŐŶŝĨŝĐĂŶƚ ?ʖ ?A? ? ? ? ? ? ? ?ĚĨ ?P = 167 
0.53). 168 
MRD is a better predictor of PFS and OS than conventional complete response 169 
To evaluate the impact of MRD status on PFS in patients who had achieved conventional CR, 170 
data were pooled from five studies involving 574 patients (396 MRD-negative, 178 MRD-171 
positive.8,25,26,28,31 For OS, data were pooled from six studies involving 616 patients (430 MRD-172 
negative, 186 MRD-positive).8,19,25,26,28,31 In patients achieving CR, the presence of MRD 173 
predicted shorter PFS (HR 0.44; 95% CI 0.34 ?0.56; P < 0.00001) (Figure 3A) and OS (HR 0.47; 174 
95% CI 0.33 ?0.67; P = 0.00006) (Figure 3B). Median PFS was 56 months for MRD-negative 175 
patients and 34 months for MRD-positive patients (Figure 3C) and median OS was 112 and 82 176 
months, respectively (Figure 3D); PFS rates were 70% and 46% at 3 years, 48% and 27% at 5 177 
years, and 37% and 14% at 7 years, respectively. Similarly, the OS rate was higher for MRD-178 
negative patients compared with MRD-positive patients at 3 years (94% vs 80%), 5 years (80% 179 
vs 61%), and 7 years (67% vs 47%). Tests of heterogeneity found no significant differences 180 
ĂŵŽŶŐƚŚĞƐƚƵĚŝĞƐĨŽƌW&^ ?ʖ2 = 2.68, 4 df; P = .61 ?ĂŶĚK^ ?ʖ2=4.22, 5 df; P = .62).  181 
Among the published analyses that were not restricted to CR patients, the impact of MRD on 182 
outcomes was less clear.12 ?14,16 ?18,29,30 One study found no significant difference in outcomes 183 
between patients with or without detectable MRD.14 Others noted that MRD status did not 184 
correlate with standard response criteria.17,18 In the study conducted by Rawstron et al.,6 it was 185 
noted that 34 of 246 (26%) MRD-negative patients did not achieve conventional CR, including 186 
29 (12%) who had less than very good partial response (VGPR). Patients who were MRD-187 
negative but failed to achieve CR had similar PFS and OS as those who were MRD-positive. 188 
Further analyses by this group suggested that log reduction in MRD (assessed as a continuous 189 
variable, rather than using a threshold for MRD positivity vs negativity), negated the 190 
significance of response in multivariate analyses for both PFS and OS.32 191 
None of the trials directly compared the ability of two different treatment approaches to 192 
induce MRD-negative status. However, five studies evaluated MRD status before and after 193 
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ASCT.6,12,17,18,20 All five indicated that ASCT increased the proportion of patients with MRD-194 
negative status.  195 
The prognostic value of MRD status in relation to other prognostic factors, e.g., high-risk 196 
cytogenetics 197 
Eleven articles reported results from univariate and/or multivariate analyses regarding the 198 
ability of MRD status to predict outcomes.13,16,18,21 ?26,28,30 In all 11 trials, MRD was shown to be a 199 
significant predictor of outcomes. Notably, only six articles mentioned cytogenetics: high-risk 200 
cytogenetics, defined as any t(4;14), t(14;16), or del(17p),33 was a negative predictor of PFS (or 201 
time to progression [TTP] or event free survival [EFS]) in 3 reports,18,24,26 and OS in 2 reports.18,26 202 
In the study by Paiva et al.,26 the combination of MRD status and cytogenetics was highly 203 
predictive of TTP, and the combination of MRD status, cytogenetics, and age was predictive of 204 
OS. Only one study reported that MRD status predicted PFS and OS in patients with unfavorable 205 
cytogenetics (defined as gain[1q], del[1p32], t[4;14], t[14;20], t[14;16], and del[17p]).6 Our 206 
meta-analysis of these latter studies6,26 indicated that the best OS is seen in patients with 207 
favorable cytogenetics who achieve MRD negativity compared with patients who are either 208 
high-risk or MRD-positive; worst results are seen in patients with high-risk cytogenetics who 209 
remain MRD-positive (P < .001) (Supplementary Figure). In a more recent analysis, cytogenetics 210 
(favorable vs unfavorable vs unknown/not evaluable) and log reduction in MRD were the only 211 
significant predictors of both PFS and OS in multivariate analysis.32  212 
The impact of maintenance therapy on MRD 213 
Ten studies mentioned maintenance therapy,6,8,12,15,17,18,25 ?27,29  but only two specifically 214 
evaluated MRD status after maintenance therapy. In one article, lenalidomide maintenance 215 
therapy was reported to increase response status in 4 patients and MRD status in 5 patients12 In 216 
the MM-IX study, more MRD-positive patients became MRD-negative during thalidomide 217 
maintenance compared with patients on no maintenance (8/29 [28%] vs 1/29 [3%]).6 218 
Furthermore, more MRD-negative patients remained MRD-negative with thalidomide 219 
maintenance than with no maintenance (24/25 [96%] vs 11/16 [69%]; P = .026).  220 
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 221 
DISCUSSION 222 
This large-cohort meta-analysis confirms that MRD status has prognostic value and is a valid 223 
surrogate marker for both PFS and OS in patients with MM, including those who had achieved a 224 
CR. All studies, irrespective of the therapies used, uniformly confirmed the impact of MRD 225 
status on outcome, indicating that the predictive value of MRD status was independent of the 226 
type of treatment used. This is consistent with the results of a recent study demonstrating that 227 
the depth of MRD is the determining factor for subsequent outcome.34 Findings from this meta-228 
analysis provide quantitative evidence to support the conceptual basis for integrating MRD 229 
assessment into the management of MM.35  230 
One of the main strengths of this analysis of pooled data from different clinical trials is the 231 
method used to generate the PFS and OS curves. These curves were adjusted for each study or 232 
group to allow for different proportions of patients with MRD positivity and negativity in the 233 
different studies, using methods described in detail elsewhere.9 This approach avoids the 234 
creation of curves that were biased inappropriately by studies with very high or very low 235 
proportions of patients with MRD positivity. 236 
This analysis did not account for the type of MRD test used in each study. Approaches to testing 237 
vary widely36; the sensitivity of different protocols also varies.4,27,36,37 However, this may 238 
represent a strength of the analysis as the results are method-agnostic, i.e., it suggests that if 239 
MRD is undetectable with a certain level of sensitivity, the results have similar significance 240 
irrespective of the method used. MFC is the most widely used method for MRD testing in MM 241 
thus far due to its broad availability, short turnaround time, and relatively low cost.3 The main 242 
limitations of this technique are its lower sensitivity (up to 1 x 10A?4 or A?5) and lack of 243 
standardization among laboratories. ASO-qPCR, although sensitive, is cumbersome and is being 244 
replaced by NGS-based MRD assessment which is more sensitive than MFC38,39 or ASO-qPCR,40 245 
and feasible in up to 90% of MM patients.41 To assess whether differences in the method of 246 
MRD assessment across the studies would impact our findings, we performed additional 247 
analyses comparing HRs for OS and PFS according to the two major methods of MRD 248 
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assessment, flow cytometry and PCR. The HR for OS in the MFC studies (n = 923) was 0.60 (95% 249 
CI 0.47 ?0.76); in the PCR studies (n = 177) it was 0.44 (95% CI 0.26 ?0.77). The HR for PFS (n = 250 
1072) in the MFC studies was 0.44 (95% CI 0.37 ?0.52); and in the PCR studies (n = 201) it was 251 
0.27 (95% CI 0.18 ?0.40). As expected, the HR is slightly greater in the PCR studies as it provides 252 
a more sensitive measurement.   253 
The studies in this analysis included primarily NDMM patients, most of whom were undergoing 254 
ASCT. The applicability of the results of this analysis in other populations, such as those with 255 
transplant-ineligible NDMM, RRMM, or high-risk cytogenetic features, is unclear. In addition, 256 
the timing of MRD assessment varied among the studies. For example, among the 14 trials 257 
included in the overall PFS meta-analysis, 5 assessed MRD before ASCT and 12 assessed MRD 258 
after ASCT. Among the trials assessing MRD after ASCT, most assessed patients after 3 months 259 
(or day 100), but some continued to assess patients every 3 to 6 months thereafter. Despite 260 
these differences, all studies showed large and consistent effects of MRD, confirmed by the 261 
non-significant ʖ2 statistic for heterogeneity, suggesting that any methodological variations 262 
between studies have a relatively minor influence on the overall MRD effect. In addition, there 263 
is always a risk in meta-analyses that negative results are less likely to have been reported, e.g. 264 
lack of effect of MRD status on OS and/or PFS.  Lastly, this analysis did not isolate the 265 
prognostic effect of MRD from those of post-transplant treatments patients may have received. 266 
Future trials will need to focus on some of these questions to determine the clinical utility of 267 
MRD assessment as well as its ability to inform treatment decisions.  268 
Assessment of MRD has several important potential applications in MM.1,42 In clinical trials, 269 
MRD assessment after initial treatment could be a useful surrogate endpoint for PFS and/or OS. 270 
It is in fact becoming an important component of the recommendations for uniform reporting 271 
of clinical trials.7 In clinical practice MRD testing may aid in prognostication; help make 272 
decisions regarding subsequent treatment, especially consolidation treatment; and, in the near 273 
future, guide the type and duration of maintenance therapy. Importantly, as the frequency of 274 
CR has increased, MRD negativity is emerging as a key endpoint for clinical studies. Integration 275 
of MRD testing into standard practice requires optimization and standardization of MRD 276 
12 
 
assessment and standardization of its timing.4,7,42 Test standardization includes establishing 277 
optimal assay methods, timing of sample collection, sensitivity requirements, thresholds for 278 
MRD-positive status, and other factors.36 For example, recent evidence suggests that MRD 279 
quantitation may be more informative than MRD status: MRC Myeloma IX trial32 demonstrated 280 
a 1-year survival benefit for each 1-log depletion in tumor burden by MFC. The questions to be 281 
addressed in future include determining the impact of different treatment approaches on MRD 282 
status (e.g., consolidation or maintenance therapy); and the prognostic importance of MRD 283 
status in relation to other known prognostic factors.  284 
In summary, the results of this large analysis showed that MRD negativity, as determined by 285 
various high-sensitivity methods, predicted better PFS and OS in patients with MM, including 286 
those who had achieved CR. MRD status is a marker of long-term outcomes in patients with 287 
MM. It should therefore be considered a new endpoint in clinical trials and clearly has a role as 288 
a surrogate marker of OS.  289 
  290 
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FIGURE LEGENDS 457 
Figure 1. Article identification and selection. AlloSCT, allogeneic stem cell transplantation; MRD, 458 
minimal residual disease; RRMM, relapsed/refractory multiple myeloma. 459 
Figure 2. Overall effect of MRD status on PFS (A) and OS (B), indicating that MRD-negative 460 
patients had better outcomes. Tests for heterogeneity indicated no significant differences 461 
between the studies for both PFS and OS. Kaplan-Meier curves for PFS (C) and OS (D); data 462 
were adjusted to account for the different proportions of patients in each study being MRD-463 
positive and MRD-negative. The sizes of the Forest plot squares represent the weighting of that 464 
trial in the meta-analysis, specifically the inverse variance of the Cox model estimate, and the 465 
horizontal lines represent the 95% CIs. CI, confidence interval; MRD, minimal residual disease; 466 
OS, overall survival; PFS, progression-free survival. 467 
Figure 3. In CR patients, effect of MRD status on PFS (A) and OS (B), indicating that MRD-468 
negative patients had better outcomes. Tests for heterogeneity indicated no significant 469 
differences between the studies for both PFS and OS. Kaplan-Meier curves for PFS (C) and OS 470 
(D); data were adjusted to account for the different proportions of patients in each study being 471 
MRD-positive and MRD-negative. The sizes of the Forest plot squares represent the weighting 472 
of that trial in the meta-analysis, specifically the inverse variance of the Cox model estimate, 473 
and the horizontal lines represent the 95% confidence intervals. CI, confidence interval; CR, 474 
complete response; MRD, minimal residual disease; OS, overall survival; PFS, progression-free 475 
survival. 476 
21 
 
Supplementary Figure. Overall survival in patients achieving CR according to cytogenetic risk 477 
category (FISH) and MRD status. CR, complete response; FISH, fluorescent in situ hybridization; 478 
MRD, minimal residual disease; OS, overall survival. 479 
